IRIS
BAGNASCO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.744
AS - Asia 1.072
NA - Nord America 497
SA - Sud America 95
AF - Africa 22
OC - Oceania 2
Totale 9.432
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.498
US - Stati Uniti d'America 470
SG - Singapore 411
CN - Cina 317
VN - Vietnam 218
FR - Francia 79
FI - Finlandia 55
BR - Brasile 52
HK - Hong Kong 39
AR - Argentina 26
DE - Germania 23
RS - Serbia 23
JP - Giappone 14
NL - Olanda 14
CA - Canada 13
MX - Messico 13
ID - Indonesia 11
BD - Bangladesh 10
GB - Regno Unito 10
IQ - Iraq 8
IN - India 7
IE - Irlanda 6
EC - Ecuador 5
ES - Italia 5
ZA - Sudafrica 5
AT - Austria 4
MA - Marocco 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CH - Svizzera 3
CL - Cile 3
JO - Giordania 3
NP - Nepal 3
PE - Perù 3
PK - Pakistan 3
RU - Federazione Russa 3
SA - Arabia Saudita 3
SN - Senegal 3
UZ - Uzbekistan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BE - Belgio 2
CY - Cipro 2
EG - Egitto 2
KZ - Kazakistan 2
PH - Filippine 2
PL - Polonia 2
PY - Paraguay 2
RO - Romania 2
SE - Svezia 2
TH - Thailandia 2
TN - Tunisia 2
TR - Turchia 2
UA - Ucraina 2
BW - Botswana 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
KE - Kenya 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 9.432
Salva come PNG Salva come JPEG
Città #
Genoa 3.041
Genova 2.913
Vado Ligure 733
Rapallo 675
San Jose 188
Singapore 167
Ashburn 69
Ho Chi Minh City 68
Hanoi 62
Lauterbourg 60
Council Bluffs 58
Helsinki 53
Beijing 42
Hong Kong 37
Bordighera 31
Belgrade 22
New York 21
Frankfurt am Main 18
Haiphong 13
Tokyo 13
Milan 11
Amsterdam 8
Da Nang 8
Los Angeles 8
Mexico City 7
Orem 7
Bologna 6
Chicago 6
Dublin 6
Rome 6
Santa Clara 6
Shanghai 6
Biên Hòa 5
East Gwillimbury 5
Madrid 5
Turin 5
Atlanta 4
Bergamo 4
Montreal 4
Ninh Bình 4
Tianjin 4
Trieste 4
Baku 3
City of London 3
Dakar 3
Hải Dương 3
Jakarta 3
Lima 3
Naples 3
Paris 3
Piscataway 3
Tampa 3
Tashkent 3
Verona 3
Vĩnh Long 3
Zurich 3
Brooklyn 2
Brussels 2
Buffalo 2
Cairo 2
Can Tho 2
Cape Town 2
Cardiff 2
Córdoba 2
Dallas 2
Durban 2
Erbil 2
Fortaleza 2
Jeddah 2
José C. Paz 2
Lahore 2
Lappeenranta 2
London 2
Mosul 2
Nice 2
Nicosia 2
Nova Milanese 2
Nuremberg 2
Phú Thọ 2
Phủ Từ Sơn 2
Querétaro 2
Quito 2
Quảng Ngãi 2
Quận Ba 2
Quận Một 2
Rio de Janeiro 2
Santiago del Estero 2
Stockholm 2
Sydney 2
São Paulo 2
Thái Bình 2
Toronto 2
Vienna 2
Villa San Giovanni 2
Waterville 2
Accra 1
Adana 1
Addis Ababa 1
Aiken 1
Almaty Region 1
Totale 8.538
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 321
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 202
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 195
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 191
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 188
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 185
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 184
Personalized medicine in allergy 179
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 179
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 177
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 172
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 165
30 Years Of Sublingual Immunotherapy 164
Current insights in allergen immunotherapy 163
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 163
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 161
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 161
Umeclidinium for the treatment of uncontrolled asthma 160
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 160
The safety of monoclonal antibodies in asthma 156
Biosimilars in allergic diseases 156
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 154
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 150
Mepolizumab in severe asthma: evidence in real-life 149
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 146
The path to personalized medicine in asthma 144
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 141
Update on immunotherapy for the treatment of asthma 135
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 132
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 130
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 129
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 126
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 124
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab 122
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 122
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 120
Biologicals for severe asthma: what we can learn from real-life experiences? 116
One year of mepolizumab. Efficacy and safety in real-life in Italy 111
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 106
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 106
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 102
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 101
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 100
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 95
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 94
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 93
Minimal clinically important difference for asthma endpoints: An expert consensus report 93
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 92
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 92
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 90
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 89
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 85
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 85
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 84
Severe asthma: One disease and multiple definitions 80
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 79
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 70
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report 70
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 67
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 64
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 62
Specific Therapy for T2 Asthma 59
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 59
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 58
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 58
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 58
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 57
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 55
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy 53
Background therapy in severe asthma on monoclonal antibody treatment in real life 53
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 52
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 51
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 51
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 51
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 50
Personalizing the approach to asthma treatment 50
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 49
null 49
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 47
SANI clinical remission definition: a useful tool in severe asthma management 46
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 44
Biologics for the Treatments of Allergic Conditions: Severe Asthma 44
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 39
Real-life studies in allergen immunotherapy 38
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 38
Strategies to reduce corticosteroid-related adverse events in asthma 36
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 36
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 34
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 34
Type 2 immunity in asthma 33
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 32
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 28
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 24
The new indications for biologicals in type 2 diseases: perspectives 23
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? 19
Strategies to reduce corticosteroid-related adverse events in asthma 18
COVID-19, Eosinophils, and Biologicals for Severe Asthma 15
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 14
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 14
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 13
Totale 9.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.338
article - articoli 34.998
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021284 0 0 0 0 0 0 0 0 0 89 46 149
2021/2022584 19 11 17 63 14 71 23 128 53 73 14 98
2022/2023814 66 74 6 67 86 126 53 37 141 53 90 15
2023/2024701 42 81 9 79 48 177 41 42 35 13 46 88
2024/20251.966 56 133 58 137 215 214 157 302 100 98 257 239
2025/20263.120 496 129 293 208 464 254 504 181 326 265 0 0
Totale 9.670